AI drug discovery company Iambic Therapeutics (formerly Entos) has raised USD 100 million in an oversubscribed Series B funding round co-led by Ascenta Capital and Abingworth, with participation from NVIDIA, Illumina Ventures, Gradiant Corporation, and other existing investors.
The proceeds will be used to advance multiple AI-discovered candidates into clinical development, expand the pipeline, and continue to build AI and automation technologies for drug discovery. The company aims to leverage NVIDIA’s technology to accelerate discovery.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.